Back to Annual Meeting

Back to Annual Meeting

Abstract #163250

Paul Johansen, MA, Hansen's Disease, Analysis & Inference, Inc, 1489 Baltimore Pike, Suite 305, Springfield, PA 19064, 484-213-1223, IguanaPhoto@aol.com

The extensive histories of Hansen's disease (HD or leprosy) institutions at Kalaupapa/Kalawao (Moloka'i, Hawaii) and Carville (Iberville Parish, Louisiana) provide parallel case studies of the ways in which stigma and public fear can interfere with the treatment of and research on a chronic infectious disease. In 1904 President Theodore Roosevelt called for the establishment of a leprosy hospital and laboratory in Hawai'i. This later produced the U.S. Leprosy Investigation Station at Kalawao – “one of the most complete laboratory outfits in the world” – which opened under the direction of Harvard pathologist Dr. Walter R. Brinckerhoff on December 23, 1909. In spite of its promise, this facility closed on August 7, 1913 without producing any new insight into HD, due in large part to a woeful lack of consideration for the concerns of potential study subjects.

Three decades later the research program at Carville succeeded where the one at Kalaupapa had failed: it staged the first positive drug trials for leprosy in 1946, demonstrating the effectiveness of sulfones against Mycobacterium leprae, the causative bacterium of leprosy. This only happened after five decades of caring for people affected by HD. Carville opened as a state facility in 1894, neighbors being told it was an ostrich farm. Authority was transferred to the U.S. Public Health Service in 1921.

In our current era, in which people worldwide are keenly attuned to the dangers of emerging infectious diseases, we must not lose sight of the important lessons learned from leprosy.

Learning Objectives:

• 1) Participants will develop an appreciation for the considerable and long-term political effort required to open and maintain treatment and research facilities for chronic infectious diseases;
• 2) Participants will begin to understand the complex and delicate interactions required to balance public needs for protection against private concerns of people affected by a chronic infectious disease; and
• 3) Participants will become attuned to the modern conditions under which the lessons learned from the U.S. experience with leprosy may again need to be applied.

Keywords: Infectious Diseases, Human Rights

Related Web page: www.IguanaPhoto.com

Presenting author's disclosure statement:

Any relevant financial relationships? No
Any institutionally-contracted trials related to this submission?

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.